Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial

TRIAL DESIGN: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Takashi, Sumi, Eriko, Egawa, Gyohei, Nakajima, Saeko, Toichi, Eiko, Inoue, Nana, Shibuya, Mami, Okamoto, Natsuko, Mitsuishi, Tsuyoshi, Uozumi, Ryuji, Tada, Harue, Nakagawa, Takayuki, Kusuba, Nobuhiro, Okuno, Aika, Shimizuhira, Chihiro, Ishikawa, Makiko, Tanaka, Shiro, Hagiwara, Masatoshi, Kabashima, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659400/
https://www.ncbi.nlm.nih.gov/pubmed/34909725
http://dx.doi.org/10.1016/j.xjidi.2021.100026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659400/
https://www.ncbi.nlm.nih.gov/pubmed/34909725
http://dx.doi.org/10.1016/j.xjidi.2021.100026

Ejemplares similares